Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

Regeneron stock has trended bearishly since ... These indications include asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, among others.

Regeneron recently announced that the primary ... Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

due to competition in the atopic dermatitis market. Additionally, it has been found that Ebglyss has a similar therapeutic value to Sanofi and Regeneron's rival treatment Dupixent (dupilumab ...

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanofi and Regeneron ...

“The Regeneron name is synonymous with innovation ... have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis ...

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD ... that the drug shares with Sanofi and Regeneron’s blockbuster AD therapy Dupixent ...